Cash cost of the wait: management is funding a defined waiting period whose end is already scheduled
The model's full reasoning — Q3 2023 call → NOWe need to determine if the transcript describes a situation where the company is currently paying for something not yet earning, with the wait being the main current work, and the far side being a specific near-dated event already visible and largely paid for. Let's analyze the transcript. Key points from management: - They are launching a COVID vaccine in the US, but it's early. They have costs associated with manufacturing, R&D, etc. - They mention "additional restructuring to create a more efficient business model" and "we are prepared to initiate additional cost reductions to decrease 2024 expenses by over $300 million above and beyond the previously stated targets for 2024." This suggests they are cutting costs, not necessarily paying for something not yet earning. - They talk about the combination COVID-influenza vaccine program. They are planning to move directly into Phase 3 in 2024, with potential launch in 2026. That is more than a year away, so not near-dated within roughly a year. - They mention "we are on track to exceed our previously announced global restructuring and cost reduction plan for 2023 by over $100 million" - that's about reducing costs, not paying for something. - They talk about the U.S. launch being early, with low market share, but they are investing in awareness. That seems like normal commercial launch costs, not a defined waiting period with a specific near-dated event. - They mention "we are prepared to further reshape and size the scope of our operations beyond previously announced 2024 targets to align with the emerging COVID market opportunity" - again, cost cutting. - They talk about the combination vaccine program as a priority, but the timeline is 2026 launch, which is beyond a year. - They mention "we are now planning to move directly into Phase 3 in 2024 and to fund this program independently." That is a future cost, not currently being paid for something not yet earning? Actually, they are planning to fund it, but the Phase 3 study is in 2024, and the benefit (launch) is in 2026. So the waiting period is more than a year. - They also mention "we are seeing early indicators" of uptake, but they are not describing a defined waiting period where they are paying for something that will start earning soon.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
SBS · Q3 2023 → YESThe question is whether management describes the company as currently living through a defined waiting period it's paying for out of its own pocket. YES The transcript shows management describing the company as currently bearing real, ongoing cash costs (salaries, consulting, transition work) for the IDP/restructuring program whose benefits (full expense reduction, shared-services center operational) are not yet realized. The far side is a specific, near-dated event: full 3.7% staff reduction and shared-services center operational by mid-2024 (July 2024 for full benefit), with the program already in motion and on schedule. Management frames this as the main current work, not a setback, and treats the costs as self-funded. This meets all three conditions.
EHTH · Q2 2021 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing the company as currently living through a defined waiting period for the AEP, paying for it out of its own pocket through heavy investments in internal agents and quality initiatives. They hired agents early, many still in training with lower productivity, and are bearing the cost of additional training and customer service expansion in Q3. This is framed as a chosen investment to improve enrollment quality and prepare for the fourth-quarter AEP, not an apology or external issue.
YUM · Q2 2018 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing a clear, self-funded transition cost tied to the refranchising effort. They explicitly call out the “timing mismatch between G&A savings and refranchising” as one of the four items weighing on Q2 core operating profit, and they quantify the full-year headwind at 6 7 percentage points. This is presented as a real, ongoing drag on current results while they complete the shift to 98 % franchised by year-end 2018 and reach the 1.7 % G&A run-rate target in 2019.